by Andrew Khouri | Jun 11, 2024 | Blog
The quest to develop new immunotherapeutic medicines relies heavily on effective preclinical research. Central to this research are in vivo animal tumor models with fully functional immune systems. Among these, syngeneic tumor models have emerged as powerful tools,...
by Andrew Khouri | Jun 4, 2024 | Blog
Antibody-drug conjugates (ADCs) have emerged as a revolutionary approach to cancer therapy. These “smart bombs” combine the targeting power of monoclonal antibodies with the potent killing ability of cytotoxic drugs. Unlike traditional chemotherapy, which...
by Andrew Khouri | May 30, 2024 | Blog
Protein kinases, the prolific signal transmitters of the cellular world, are more than just tiny molecular machines. With around 518 types identified in humans, they form one of the largest and most significant families of proteins, playing crucial roles in regulating...
by Andrew Khouri | May 15, 2024 | Blog
Over 70% of cases of bladder cancer (BC) are initially diagnosed at non-muscle-invasive stages (NIMBC). These are typically managed through local treatments like intravesical instillation. Therefore, subcutaneous models may not be applicable for research in NMIBC....
by Andrew Khouri | Apr 3, 2024 | News
~ Reaction Biology will also present 15 posters and exhibit at Booth #141 in the Exhibit Hall ~ Malvern, PA, April 3, 2024 – Reaction Biology (“Reaction” or the “Company”), an industry-leading provider of drug discovery and development services, today announced...
